Global Leukemia Therapeutics Market Size & Outlook

The global leukemia therapeutics market size was estimated at USD 16,478.4 million in 2024 and is projected to reach USD 36,019.9 million by 2033, growing at a CAGR of 7.4% from 2025 to 2033.
Revenue, 2024 (US$M)
$16,478.4
Forecast, 2033 (US$M)
$36,019.9
CAGR, 2025 - 2033
7.4%
Report Coverage
Worldwide

Global leukemia therapeutics market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Global leukemia therapeutics market highlights

  • The global leukemia therapeutics market generated a revenue of USD 16,478.4 million in 2024 and is expected to reach USD 36,019.9 million by 2033.
  • The market is expected to grow at a CAGR (2025 - 2033) of 7.4% by 2033.
  • In terms of segment, chronic lymphocytic leukemia (cll) accounted for a revenue of USD 6,077.6 million in 2024.
  • Acute Lymphocytic Leukemia (ALL) is the most lucrative type segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2024.
  • Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2033.

Global data book summary

Market revenue in 2024USD 16,478.4 million
Market revenue in 2033USD 36,019.9 million
Growth rate7.4% (CAGR from 2025 to 2033)
Largest segmentChronic lymphocytic leukemia (cll)
Fastest growing segmentAcute Lymphocytic Leukemia (ALL)
Historical data covered2021 - 2023
Base year for estimation2024
Forecast period covered2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationChronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Others Type

Other key industry trends

  • In terms of revenue, the North America accounted for 34.3% of the global leukemia therapeutics market in 2024.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
  • By country, Mexico is the fastest growing regional market and is projected to reach USD 423.3 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Leukemia Therapeutics Market Companies

Name Profile # Employees HQ Website
Takeda Pharmaceutical Co Ltd View profile 49095 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 https://www.takeda.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
Bristol-Myers Squibb Co View profile 34100 Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 https://www.bms.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Amgen Inc View profile 26700 One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 https://www.amgen.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Global leukemia therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to leukemia therapeutics market will help companies and investors design strategic landscapes.


Chronic lymphocytic leukemia (cll) was the largest segment with a revenue share of 36.88% in 2024. Horizon Databook has segmented the Global leukemia therapeutics market based on chronic myeloid leukemia (cml), chronic lymphocytic leukemia (cll), acute lymphocytic leukemia (all), acute myeloid leukemia (aml), others type covering the revenue growth of each sub-segment from 2021 to 2033.


  • Global Leukemia Therapeutics Type Outlook (Revenue, USD Million, 2021-2033)
    • Chronic Myeloid Leukemia (CML)
    • Chronic Lymphocytic Leukemia (CLL)
    • Acute Lymphocytic Leukemia (ALL)
    • Acute Myeloid Leukemia (AML)
    • Others Type
  • Global Leukemia Therapeutics Treatment Outlook (Revenue, USD Million, 2021-2033)
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Others Treatment
  • Global Leukemia Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Others Distribution Channel

Reasons to subscribe to Global leukemia therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global leukemia therapeutics market databook

  • Our clientele includes a mix of leukemia therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global leukemia therapeutics market , including forecasts for subscribers. This global databook contains high-level insights into Global leukemia therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global leukemia therapeutics market size, by regions, 2021-2033 (US$M)

Top 10 countries: Leukemia therapeutics market size, 2024 (US$M)

Global leukemia therapeutics market share, by type, 2024 & 2033 (%, US$M)

Leukemia therapeutics market: Opportunity assessment by country

Global leukemia therapeutics market, by region, 2024 (US$M)

Global leukemia therapeutics market size, by regions, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online